Revenue exceeded analyst estimates by 98%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Looking ahead, ...

BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

In a recent transaction, an executive at Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) sold a significant amount of company stock, according to a new SEC filing. Mark E. Dmytruk, the ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...